These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 25985938)

  • 1. Colorectal cancer: POLR2A deletion with TP53 opens a window of opportunity for therapy.
    Errico A
    Nat Rev Clin Oncol; 2015 Jul; 12(7):374. PubMed ID: 25985938
    [No Abstract]   [Full Text] [Related]  

  • 2. TP53 loss creates therapeutic vulnerability in colorectal cancer.
    Liu Y; Zhang X; Han C; Wan G; Huang X; Ivan C; Jiang D; Rodriguez-Aguayo C; Lopez-Berestein G; Rao PH; Maru DM; Pahl A; He X; Sood AK; Ellis LM; Anderl J; Lu X
    Nature; 2015 Apr; 520(7549):697-701. PubMed ID: 25901683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colorectal cancer: A circuitous way to target p53.
    Seton-Rogers S
    Nat Rev Cancer; 2015 Jun; 15(6):318-9. PubMed ID: 25971675
    [No Abstract]   [Full Text] [Related]  

  • 4. Cancer: An essential passenger with p53.
    Bradner JE
    Nature; 2015 Apr; 520(7549):626-7. PubMed ID: 25901678
    [No Abstract]   [Full Text] [Related]  

  • 5. A new way to target p53-defective colorectal cancer.
    Liu Y; Wang L; Lu X
    Future Oncol; 2015; 11(23):3101-4. PubMed ID: 26549592
    [No Abstract]   [Full Text] [Related]  

  • 6. [p53 and Rb, clinical and therapeutic perspectives].
    Soussi T; Caron de Fromentel C
    Pathol Biol (Paris); 1993 Jan; 41(1):25-6. PubMed ID: 8316455
    [No Abstract]   [Full Text] [Related]  

  • 7. Deletions linked to TP53 loss drive cancer through p53-independent mechanisms.
    Liu Y; Chen C; Xu Z; Scuoppo C; Rillahan CD; Gao J; Spitzer B; Bosbach B; Kastenhuber ER; Baslan T; Ackermann S; Cheng L; Wang Q; Niu T; Schultz N; Levine RL; Mills AA; Lowe SW
    Nature; 2016 Mar; 531(7595):471-475. PubMed ID: 26982726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression of phosphoprotein P53 in pathology].
    Casazza S
    Pathologica; 1993; 85(1097):321-34. PubMed ID: 8233649
    [No Abstract]   [Full Text] [Related]  

  • 9. Over-expression of p53 protein in neoplastic changes in ulcerative colitis: immunohistochemical study.
    Ajioka Y; Watanabe H; Matsuda K
    J Gastroenterol; 1995 Nov; 30 Suppl 8():33-5. PubMed ID: 8563884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The expression of mutation p53 gene from circulating cancer cells of peripheral blood and the clinical significance in detecting the patients with colorectal cancer].
    Ma GJ; Zhou JN; Shen ZL; Chen SQ; Zhu YQ; Wu XL; Xue KX
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):186-8. PubMed ID: 16604493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [TP53 mutations and molecular epidemiology].
    Otsuka K; Ishioka C
    Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Association of TP53 gene polymorphisms with genetic susceptibility to liver metastases of colorectal cancer].
    Wang AZ; Zhu ZZ; Cong WM
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Apr; 25(2):168-71. PubMed ID: 18393238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rare MDM4 gene amplification in colorectal cancer: The principle of a mutually exclusive relationship between MDM alteration and TP53 inactivation is not applicable.
    Suda T; Yoshihara M; Nakamura Y; Sekiguchi H; Godai TI; Sugano N; Tsuchida K; Shiozawa M; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Matsukuma S; Miyagi Y
    Oncol Rep; 2011 Jul; 26(1):49-54. PubMed ID: 21503588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic polymorphisms in TP53, nonsteroidal anti-inflammatory drugs and the risk of colorectal cancer: evidence for gene-environment interaction?
    Tan XL; Nieters A; Hoffmeister M; Beckmann L; Brenner H; Chang-Claude J
    Pharmacogenet Genomics; 2007 Aug; 17(8):639-45. PubMed ID: 17622940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
    García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V
    Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Tumor Suppressor p53 Limits Ferroptosis by Blocking DPP4 Activity.
    Xie Y; Zhu S; Song X; Sun X; Fan Y; Liu J; Zhong M; Yuan H; Zhang L; Billiar TR; Lotze MT; Zeh HJ; Kang R; Kroemer G; Tang D
    Cell Rep; 2017 Aug; 20(7):1692-1704. PubMed ID: 28813679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Familial and nutritional risk factors for p53 overexpression in colorectal cancer.
    Freedman AN; Michalek AM; Marshall JR; Mettlin CJ; Petrelli NJ; Black JD; Zhang ZF; Satchidanand S; Asirwatham JE
    Cancer Epidemiol Biomarkers Prev; 1996 Apr; 5(4):285-91. PubMed ID: 8722220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal p53 immunohistochemistry is associated with an increased colorectal cancer-related mortality in patients with ulcerative colitis.
    Lashner BA; Bauer WM; Rybicki LA; Goldblum JR
    Am J Gastroenterol; 2003 Jun; 98(6):1423-7. PubMed ID: 12818291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Record no. 39: p53 (TP53)].
    Soussi T
    Bull Cancer; 2000 Oct; 87(10):691-2. PubMed ID: 11185522
    [No Abstract]   [Full Text] [Related]  

  • 20. P53 abnormalities and outcomes in colorectal cancer: a systematic review.
    Smith FM; Stephens RB; Kennedy MJ; Reynolds JV
    Br J Cancer; 2005 May; 92(9):1813. PubMed ID: 15856032
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.